The 4th Joint Session between JDDW-KDDW-TDDW4(JDDW)
Thu. November 5th   14:00 - 16:15   Room 10: Portopia Hotel Waraku
JKT4-2
 Current Treatment Strategies for Hepatocellular Carcinoma in Korea
Bo Hyun Kim
Center for Liver and Pancreatobiliary Cancer, National Cancer Center
Primary liver cancer is the second most common cause of cancer mortality in South Korea.1 Approximately 16,000 patients are diagnosed with primary liver cancer each year and about 11,000 patients still die from primary liver cancer every year.2 Hepatitis B virus (HBV) is the predominant etiology of hepatocellular carcinoma (HCC), accounting for approximately 70% of cases.2
The Korean Liver Cancer Association-National Cancer Center practice guidelines for the management of hepatocellular carcinoma were firstly released in 2003 and have been revised three times in 2009, 2014, and 2018. The Korean practice guideline for HCC adopts the modified UICC stages as a primary staging system and recommends the best and alternative options for each modified UICC stage (Figure 1).3 These recommendations are primarily for patients with good liver function (e.g. Child-Pugh class A) and performance status since the treatment may vary depending on underlying liver disease and performance status as well as the patient’s tumor status.
Nowadays, evidence for new drugs and treatments regarding HCC is accumulating and the current strategies are modifying on the basis of new evidence.
Page Top